Predix begins phase 1 trial of PRX-07034 in obesity

By Lisa Kerner

Charlotte, N.C., June 7 - Predix Pharmaceuticals said it has started a phase 1 clinical trial in 18 male and female volunteers to study the safety, tolerability and pharmacokinetics of PRX-07034, a serotonin 5-HT6 antagonist being developed for the treatment of obesity and also for cognitive impairment (associated with Alzheimer's disease or schizophrenia).

"PRX-07034 is the fourth novel drug candidate emerging from our discovery platform and progressing rapidly into human clinical trials," president and chief executive officer Michael G. Kauffman said in a company news release.

"This particular candidate selectively targets the serotonin 5-HT6 protein receptor, which is found primarily in the brain with little or no expression in peripheral tissues."

Results from the phase 1 trial are expected later this year, officials said.

Located in Lexington, Mass., Predix is a pharmaceutical company focused on small-molecule drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.